234 related articles for article (PubMed ID: 37310268)
41. Sub-MIC levels of bedaquiline and clofazimine can select
Villellas C; Stevenaert F; Remmerie B; Andries K
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194
[TBL] [Abstract][Full Text] [Related]
42. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
44. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
45. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Li J; Yang G; Cai Q; Wang Y; Xu Y; Zhang R; Lang Y; Cai X
Int J Infect Dis; 2021 Sep; 110():179-186. PubMed ID: 34293490
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
Ali AM; P Solans B; Hesseling AC; Winckler J; Schaaf HS; Draper HR; van der Laan L; Hughes J; Fourie B; Nielsen J; Wiesner L; Garcia-Prats AJ; Savic RM
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0079423. PubMed ID: 38112526
[TBL] [Abstract][Full Text] [Related]
47. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.
Tanneau L; Svensson EM; Rossenu S; Karlsson MO
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526
[TBL] [Abstract][Full Text] [Related]
48. The effect of anti-tuberculosis drug pharmacokinetics on QTc prolongation.
Jin Y; Benkeser D; Kipiani M; Maranchick NF; Mikiashvili L; Barbakadze K; Avaliani Z; Alghamdi WA; Alshaer MH; Peloquin CA; Blumberg HM; Kempker RR
Int J Antimicrob Agents; 2023 Oct; 62(4):106939. PubMed ID: 37517627
[TBL] [Abstract][Full Text] [Related]
49. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
[TBL] [Abstract][Full Text] [Related]
50. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
[TBL] [Abstract][Full Text] [Related]
52. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.
Olayanju O; Esmail A; Limberis J; Dheda K
Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31619478
[TBL] [Abstract][Full Text] [Related]
53. Sudapyridine (WX-081), a Novel Compound against Mycobacterium tuberculosis.
Yao R; Wang B; Fu L; Li L; You K; Li YG; Lu Y
Microbiol Spectr; 2022 Feb; 10(1):e0247721. PubMed ID: 35170994
[TBL] [Abstract][Full Text] [Related]
54. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
55. Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis.
Putra ON; Yulistiani Y; Soedarsono S
Int J Mycobacteriol; 2022; 11(4):349-355. PubMed ID: 36510917
[TBL] [Abstract][Full Text] [Related]
56. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
[TBL] [Abstract][Full Text] [Related]
57. A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.
Shim TS; Pai H; Mok J; Lee SH; Kwon YS; Choi JC; Park J; Birmingham E; Mao G; Alquier L; Davis K; Thoret-Bauchet F; Kim JH; Kim H; Bakare N
BMC Infect Dis; 2023 Jan; 23(1):15. PubMed ID: 36624432
[TBL] [Abstract][Full Text] [Related]
58. INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES.
Asfaw MT; Holtzman DL; Kwan GF; Oyewusi LT; Mitnick CD; Seung KJ
Afr J Infect Dis; 2021; 15(2 Suppl):38-41. PubMed ID: 34595385
[TBL] [Abstract][Full Text] [Related]
59. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
60. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
